Clinical Trial Update: Differential Immune Effects of Natalizumab

View source ↗

Summary

This completed trial update reports differential immune effects observed with Natalizumab in relapsing-remitting multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: Cantonal Hospital of St. Gallen | Conditions: Multiple Sclerosis, Relapsing Remitting | Status: COMPLETED